Drug intelligence / Profile preview

BI 754132

Development stage: Discontinued
Lead developer: Boehringer Ingelheim
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravitreal

Overview

BI 754132 is a humanized monoclonal IgG1 antibody developed by Boehringer Ingelheim for the treatment of age-related macular degeneration, specifically targeting geographic atrophy secondary to this condition. Its mechanism of action involves agonistic activity at the tropomyosin-related kinase receptor type B (TrkB), mimicking the effects of brain-derived neurotrophic factor (BDNF). This activation leads to phosphorylation and downstream signaling that promotes cell survival and potentially synaptogenesis in retinal cells. The drug was administered via intravitreal injection in clinical trials but development has been discontinued after phase I studies[1][2][3][8].

Targets

NTRK2 (Tropomyosin-related kinase receptor type B)

Beyond the preview

Go deeper on BI 754132.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 754132.

Explore the full profile